Cardiogen vs Ventfort
Comparison of Cardiogen (Low evidence) and Ventfort (Very Low evidence).
Last updated: February 12, 2026
Cardiogen
Ventfort
Overview
Cardiogen and Ventfort are both studied in the peptide research space.
Cardiogen: A synthetic tripeptide (Ala-Glu-Asp) developed by Russian scientist Vladimir Khavinson for cardiac tissue support.
Ventfort: A cytamin-class peptide supplement derived from blood vessel tissue, part of the Russian bioregulator framework.
Evidence Comparison
| Aspect | Cardiogen | Ventfort |
|---|---|---|
| Evidence Level | Low | Very Low |
| Human Studies | 2 | 0 |
| Preclinical Studies | 8 | 5 |
| Total Sources | 12 | 6 |
Key Differences
| Aspect | Cardiogen | Ventfort |
|---|---|---|
| Category | Other | Other |
| Evidence Strength | Low | Very Low |
| Total Sources | 12 | 6 |
| Human Studies | 2 | 0 |
Summary
- Cardiogen: Low evidence with 12 total sources (2 human)
- Ventfort: Very Low evidence with 6 total sources (0 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.